Cargando…
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315268/ http://dx.doi.org/10.1186/1479-5876-13-S1-O4 |
| _version_ | 1782355448480923648 |
|---|---|
| author | Ascierto, Paolo A McArthur, Grant A Dréno, Brigitte Larkin, James Liszkay, Gabriella Maio, Michele Mandala, Mario Demidov, Lev Stroyakovskiy, Daniil Thomas, Luc de la Cruz-Merino, Luis Atkinson, Victoria Dutriaux, Caroline Garbe, Claus Chang, Ilsung Hack, Stephen P Ribas, Antoni |
| author_facet | Ascierto, Paolo A McArthur, Grant A Dréno, Brigitte Larkin, James Liszkay, Gabriella Maio, Michele Mandala, Mario Demidov, Lev Stroyakovskiy, Daniil Thomas, Luc de la Cruz-Merino, Luis Atkinson, Victoria Dutriaux, Caroline Garbe, Claus Chang, Ilsung Hack, Stephen P Ribas, Antoni |
| author_sort | Ascierto, Paolo A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4315268 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-43152682015-02-12 coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) Ascierto, Paolo A McArthur, Grant A Dréno, Brigitte Larkin, James Liszkay, Gabriella Maio, Michele Mandala, Mario Demidov, Lev Stroyakovskiy, Daniil Thomas, Luc de la Cruz-Merino, Luis Atkinson, Victoria Dutriaux, Caroline Garbe, Claus Chang, Ilsung Hack, Stephen P Ribas, Antoni J Transl Med Oral Presentation BioMed Central 2015-01-15 /pmc/articles/PMC4315268/ http://dx.doi.org/10.1186/1479-5876-13-S1-O4 Text en Copyright © 2015 Ascierto et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Ascierto, Paolo A McArthur, Grant A Dréno, Brigitte Larkin, James Liszkay, Gabriella Maio, Michele Mandala, Mario Demidov, Lev Stroyakovskiy, Daniil Thomas, Luc de la Cruz-Merino, Luis Atkinson, Victoria Dutriaux, Caroline Garbe, Claus Chang, Ilsung Hack, Stephen P Ribas, Antoni coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) |
| title | coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) |
| title_full | coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) |
| title_fullStr | coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) |
| title_full_unstemmed | coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) |
| title_short | coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) |
| title_sort | cobrim: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated braf(v600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (nct01689519) |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315268/ http://dx.doi.org/10.1186/1479-5876-13-S1-O4 |
| work_keys_str_mv | AT asciertopaoloa cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT mcarthurgranta cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT drenobrigitte cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT larkinjames cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT liszkaygabriella cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT maiomichele cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT mandalamario cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT demidovlev cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT stroyakovskiydaniil cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT thomasluc cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT delacruzmerinoluis cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT atkinsonvictoria cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT dutriauxcaroline cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT garbeclaus cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT changilsung cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT hackstephenp cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 AT ribasantoni cobrimaphase3doubleblindplacebocontrolledstudyofvemurafenibversusvemurafenibcobimetinibinpreviouslyuntreatedbrafv600mutationpositivepatientswithunresectablelocallyadvancedormetastaticmelanomanct01689519 |